# Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/infliximab-chimeric-anti-tumour-necrosis-factor-monoclonal-antibody-versus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ravinder N. Maini,E. William St. Clair,Ferdinand C. Breedveld,Daniel E. Fürst,Joachim R. Kalden,Michael H. Weisman,Josef S. Smolen,Paul Emery,Gregory R. Harriman,Marc Feldmann,Peter E. Lipsky |
| Citations | 2,360 |
| DOI | 10.1016/s0140-6736(99)05246-0 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1985763670 |
| PMID | 10622295 |
| Type | article |
| Year | 1999 |

## Paper authors

- [Peter E. Lipsky](https://scholariq.org/researchers/peter-e-lipsky/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.